Defendant
7 cases as defendant.
Aurobindo Pharma Limited ("Aurobindo"; NSE/BSE: AUROPHARMA) is an India-based pharmaceutical manufacturer headquartered in Hyderabad, Telangana, incorporated in 1986 and publicly listed on the Indian exchanges. Third-party profiles put recent revenue near US$3.8–3.9 billion and market capitalization around US$9 billion; reported headcount varies widely by source (roughly 28,000 to 46,000), so employee figures should be treated as approximate.
Operations. Aurobindo is a vertically integrated generics manufacturer, with formulations (about 80% of revenue) and active pharmaceutical ingredients (APIs, about 20%). Formulations span oral solids, injectables and OTC products, with therapeutic focus on CNS, cardiovascular, anti-diabetics, gastroenterology, anti-infectives and anti-retrovirals (HIV). It also supplies APIs and intermediates externally, and subsidiaries pursue biosimilars (CuraTeQ Biologics) and branded oncology (Acrotech Biopharma). It operates manufacturing facilities in India, the U.S., Portugal and Brazil and exports to roughly 150 countries, with the U.S. as its largest market.
Litigation posture. Aurobindo is an operating company and a pure defendant in this dataset: 0 cases as plaintiff, 2 as defendant, both in the District of Delaware — a standard Hatch-Waxman venue, not a plaintiff-friendly NPE district such as the Eastern District of Texas. Both tracked suits are ANDA patent-infringement actions brought by Merck entities, consistent with a generic manufacturer defending against innovator patent enforcement rather than asserting patents.
Notable cases. Merck KGaA, Merck Serono SA and Ares Trading SA v. Hopewell Pharma Ventures, Inc., et al. (D. Del., filed Oct 17, 2022) named Aurobindo alongside Hopewell and Apotex and asserted U.S. Patents 7,713,947 and 8,377,903 covering Merck's Mavenclad (cladribine). The parallel Aurobindo-specific action, Merck KGaA et al. v. Aurobindo Pharma USA, Inc. et al. (D. Del.), was consolidated with it. Hopewell's IPRs invalidated the asserted claims; the Federal Circuit affirmed in October 2025, and the district court stayed the consolidated actions pending resolution. Aurobindo is also a named defendant in separate consolidated sugammadex (Bridion, RE44,733) ANDA litigation.
Original complaint asserted '919; plaintiffs ceased asserting the '919 patent against all defendants. The consolidated case was later globally stayed pending IPR appeals on the '947 and '903 patents.
Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).
Hatch-Waxman ANDA infringement action by Celgene against Aurobindo; consolidated with the 2019 wave and later resolved by a Celgene-Aurobindo settlement in spring 2021.
Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.
D. Del. action asserting the '725 patent against Aurobindo; listed in some databases under Cipla. Settled/terminated.
Lilly filed a petition against Aurobindo (along with Lupin) on November 24, 2008, in the Cymbalta/duloxetine HCl ANDA litigation involving US 5,023,269. The case was resolved by the April 27, 2011 order/dismissals (docket not confirmed).
Consolidated into 22-1365. The '919 patent was asserted in the original complaint but dropped; the consolidated case involved the '947 and '903 patents.